Bluejay Therapeutics

Bluejay Therapeutics is a private biopharmaceutical company focused on developing treatments for infectious diseases. The company's first target indication is chronic hepatitis B, a globally prevalent disease with an urgent unmet medical need. Bluejay Therapeutics is advancing two innovative approaches with high potential for functional cure rates: a first-in-class fully human IgG1 anti-HBs monoclonal antibody and a first-in-class oral small-molecule HBsAg inhibitor. The company believes that functional cure in patients can be achieved by reducing hepatitis B surface antigen and restoring adaptive immunity.